Who
Timothy McInerney
Director
Company insider
Files Form 4 as: Director, Silence Therapeutics; Director, Emisphere Technologies; Director, Insite Vision; Director, Alaunos Therapeutics; Director, TG Therapeutics.
In numbers
- Trades disclosed
- 77
- Buys
- 4
- Sells
- 0
- Bought
- $366K
- Sold
- $0
- Companies
- 5
- Companies where not an officer
- 5
- First trade
- 1 Feb 2006
- Last trade
- 2 Jan 2026
- Last filed
- 6 Jan 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Jan 2026filed 6 Jan 2026 | SLN Silence Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —90,000 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | SLN Silence Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —90,000 at $0.00 | filing |
| 5 May 2025filed 20 May 2025 | SLN Silence Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —48,000 at $0.00 | filing |
| 18 May 2017filed 24 May 2017 | Emisphere Technologiesoption or derivative | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 25 May 2016filed 26 May 2016 | Emisphere Technologiesoption or derivative | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 2 Nov 2015filed 4 Nov 2015 | Insite Visionoption or derivative | SEC FORM 4 Code D | —30,000 | filing |
| 2 Nov 2015filed 4 Nov 2015 | Insite Visionoption or derivative | SEC FORM 4 Code D | —150,000 | filing |
| 2 Nov 2015filed 4 Nov 2015 | Insite Visionoption or derivative | SEC FORM 4 Code D | $53K150,000 at $0.35 | filing |
| 2 Nov 2015filed 4 Nov 2015 | Insite Visionoption or derivative | SEC FORM 4 Code D | —150,000 | filing |
| 2 Nov 2015filed 4 Nov 2015 | Insite Visionoption or derivative | SEC FORM 4 Code D | $53K150,000 at $0.35 | filing |
| 2 Nov 2015filed 4 Nov 2015 | Insite Visionoption or derivative | SEC FORM 4 Code D | $53K150,000 at $0.35 | filing |
| 2 Nov 2015filed 4 Nov 2015 | Insite Visionoption or derivative | SEC FORM 4 Code D | $53K150,000 at $0.35 | filing |
| 2 Nov 2015filed 4 Nov 2015 | Insite Visionoption or derivative | SEC FORM 4 Code D | $2,66766,666 at $0.04 | filing |
| 2 Nov 2015filed 4 Nov 2015 | Insite Visionoption or derivative | SEC FORM 4 Code D | $72K287,357 at $0.25 | filing |
| 2 Nov 2015filed 4 Nov 2015 | Insite Visionoption or derivative | SEC FORM 4 Code D | $98K362,319 at $0.27 | filing |
| 2 Nov 2015filed 4 Nov 2015 | Insite Visionoption or derivative | SEC FORM 4 Code D | $129K444,445 at $0.29 | filing |
| 28 Oct 2015filed 30 Oct 2015 | Insite Vision | SEC FORM 4 Code U | $210K600,786 at $0.35 | filing |
| 20 May 2015filed 26 May 2015 | Emisphere Technologiesoption or derivative | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 3 Mar 2015filed 5 Mar 2015 | Emisphere Technologiesoption or derivative | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 31 Dec 2014filed 2 Jan 2015 | TCRT Alaunos TherapeuticsBiotechnology | SEC FORM 4 Code A | —16,707 at $0.00 | filing |
News
Biotech Stock Alaunos Therapeutics (NASDAQ: TCRT) Sees Triple Digit Gains on Acquisition and FundingTCRT · investorideas.com · 13 Oct 2026Alaunos Therapeutics Announces Acquisition of Velaris TherapeuticsTCRT · manilatimes.net · 13 Oct 2026
0 headlines in the last 90 days name Timothy McInerney; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.